CRANFORD, N.J., Feb. 3, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a
specialty pharmaceutical company focused on adjunctive cancer care
and critical care drug products, announced that it received notice
from The Nasdaq Stock Market LLC ("NASDAQ") on January 31,
2020 indicating that the Company has regained compliance with
the minimum bid price requirement under NASDAQ Listing Rule
5550(a)(2) (the "Bid Price Rule") for continued listing on The
NASDAQ Capital Market. Accordingly, the Company has regained
compliance with the Bid Price Rule and NASDAQ considers the matter
closed.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives, cancer care, and unique prescription
products that use innovative, patented, or proprietary formulations
of previously-approved active pharmaceutical ingredients. We seek
to achieve leading market positions by providing therapeutic
products that address unmet medical needs. By using
previously approved drugs with substantial safety and efficacy
data, we seek to reduce the risks associated with pharmaceutical
product development and regulatory requirements. Citius develops
products that have intellectual property protection and competitive
advantages to existing therapeutic approaches. For more
information, please visit www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
are made based on our expectations and beliefs concerning future
events impacting Citius. You can identify these statements by the
fact that they use words such as "will," "anticipate," "estimate,"
"expect," "should," and "may" and other words and terms of similar
meaning or use of future dates. Forward-looking statements are
based on management's current expectations and are subject to risks
and uncertainties that could negatively affect our business,
operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: risks associated with continuing
to meet the listing requirements of The Nasdaq Capital Market;
risks associated with conducting our Phase 3 trial for Mino-Lok,
including completing patient enrollment, opening study sites and
achieving the required number of catheter failure events; the
estimated markets for our product candidates and the acceptance
thereof by any market; our need for substantial additional funds;
risks associated with developing Mino-Wrap, including that
preclinical results may not be predictive of clinical results and
our ability to file an IND; risks related to our growth strategy;
our ability to identify, acquire, close and integrate product
candidates and companies successfully and on a timely basis; risks
relating to the results of research and development activities;
uncertainties relating to preclinical and clinical testing; the
early stage of products under development; our ability to obtain,
perform under and maintain financing and strategic agreements and
relationships; our ability to attract, integrate, and retain key
personnel; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
Contact:
Andrew
Scott
Vice President, Corporate
Development
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements-300997231.html
SOURCE Citius Pharmaceuticals, Inc.